Cas:75240-12-9 acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine manufacturer & supplier

Chemical Name:acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine

CAS.NO:75240-12-9

Synonyms:acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine

Molecular Formula:C₁₆H₁₉N₃O₂

Molecular Weight:285.34100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:461.4ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:92.73000

Exact Mass:285.14800

LogP:3.27180

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine Use and application,acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine technical grade,usp/ep/jp grade.

Related News: The move follows a Class I recall, the FDA’s most serious, launched by Innova in late April amid “significant concerns” about the test’s accuracy—and alongside an official warning letter delivered to the company this week. acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine manufacturer The move follows a Class I recall, the FDA’s most serious, launched by Innova in late April amid “significant concerns” about the test’s accuracy—and alongside an official warning letter delivered to the company this week. acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine supplier Lilly has denied retaliating against any employees, and no lawsuit has been filed on behalf of Mula. acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine vendor Lilly has denied retaliating against any employees, and no lawsuit has been filed on behalf of Mula. acetic acid,1-propyl-5H-pyrido[4,3-b]indol-3-amine factory The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions.